VXRT - Vaxart draws bullish rating from Cantor on prospects for oral vaccines

Cantor Fitzgerald has initiated the coverage of Vaxart (VXRT +0.8%) with an Overweight recommendation noting the prospects of the company’s vaccine candidates for norovirus and SARS-CoV-2. The company focused on orally-administered vaccines has potential to take programs toward market opportunities worth over $1B, the analyst Charles C. Duncan argues. An underpenetrated market for initial and booster shots given the lack of differentiation of current products has prompted his bullish views on COVID-19 vaccine candidate. For vaccine candidate for norovirus, there is an untapped market with no approved vaccines, the analyst notes. The 12-month price target of $15 per share implies a premium of ~108.0% to the last close. Early October, Vaxart (NASDAQ:VXRT) announced the beginning of recruitment in Phase 2 trial for its oral COVID-19 vaccine candidate.

For further details see:

Vaxart draws bullish rating from Cantor on prospects for oral vaccines